NDA 207947 · Actelion
Uptravi
Selexipag · Oral · Prostacyclin Receptor Agonist
NovelOrphanLast checked: Nov 20, 2026Latest source record: May 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Dec 21, 2015
Approved uses
3
Original approval plus efficacy supplements
Registered trials
28
9 Phase 3, 3 recruiting
FAERS reports
26,100
19,535 serious, 4,907 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 28, 2026.
UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I): In adults to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) In pediatric patients aged 2 years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) 1.1 Pulmonary Arterial Hypertension Adult Patients UPTRAVI is indicated for the treatment of pulmonary arterial hypertension in adults (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness of UPTRAVI tablets was established in a long-term study in adult PAH patients with WHO Functional Class II–III symptoms. Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), PAH associated with congenital heart disease with repaired shunts (10%) [see Clinical Studies (14.1) ] . Pediatric Patients UPTRAVI is indicated for the treatment of PAH (WHO Group I) in pediatric patients aged two years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH.
Mechanism: Selexipag is a prostacyclin receptor (IP receptor) agonist that is structurally distinct from prostacyclin. Selexipag is hydrolyzed by carboxylesterase 1 to yield its active metabolite, which is approximately 37-fold as potent as selexipag. Selexipag and the active metabolite are selective for the IP receptor versus other prostanoid receptors (EP 1–4 , DP, FP, and TP).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 23, 2026 Supplement 14 · Efficacy · priority review OrphanLetterLabel
- Jan 30, 2021 Supplement 8 · Efficacy OrphanLabelLetter
- Dec 21, 2015 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewSummary Review
10 products under this application
- UPTRAVI · SELEXIPAG 0.2MG · TABLET, ORAL · Prescription · TE AB
- UPTRAVI · SELEXIPAG 1.6MG · TABLET, ORAL · Prescription · TE AB
- UPTRAVI · SELEXIPAG 1.2MG · TABLET, ORAL · Prescription · TE AB
- UPTRAVI · SELEXIPAG 0.8MG · TABLET, ORAL · Prescription · TE AB
- UPTRAVI · SELEXIPAG 0.1MG · TABLET, ORAL · Prescription
- UPTRAVI · SELEXIPAG 0.4MG · TABLET, ORAL · Prescription · TE AB
- UPTRAVI · SELEXIPAG 1.4MG · TABLET, ORAL · Prescription · TE AB
- UPTRAVI · SELEXIPAG 1MG · TABLET, ORAL · Prescription · TE AB
- UPTRAVI · SELEXIPAG 0.15MG · TABLET, ORAL · Prescription
- UPTRAVI · SELEXIPAG 0.6MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Selexipag" as an intervention, any sponsor and status, largest first.
- Selexipag (ACT-293987) in Pulmonary Arterial HypertensionPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01106014 · 1,156 participants · Start Dec 1, 2009 · Primary completion Apr 1, 2014
Drug: Selexipag; Placebo · For: Pulmonary Arterial Hypertension
Sites: Mobile, Alabama; Tucson, Arizona; La Jolla, California · 182 sites in all
- ACT-293987 in Pulmonary Arterial HypertensionPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01112306 · 709 participants · Start Jul 7, 2010 · Primary completion Aug 26, 2021
Drug: ACT-293987 · For: Pulmonary Arterial Hypertension
Sites: Mobile, Alabama; Phoenix, Arizona; Tucson, Arizona · 157 sites in all
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionPivotal-lookingRecruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT05179876 · 280 participants (planned) · Start May 4, 2022 · Primary completion Jan 31, 2027
Drug: Macitentan; Selexipag and 1 more · For: Hypertension, Pulmonary
Sites: Minsk, Belarus; Leuven, Belgium; Sofia, Bulgaria · 45 sites in all
- The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial HypertensionPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT02558231 · 247 participants · Start May 1, 2016 · Primary completion Aug 29, 2019
Drug: Macitentan; Tadalafil and 1 more · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 58 sites in all
- Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial HypertensionPivotal-lookingRecruiting
University of Sao Paulo General HospitalAcademic, hospital or other
NCT07713914 · 196 participants (planned) · Start Jul 22, 2026 · Primary completion Jul 1, 2028
Drug: Prostacyclin Pathway Agent; Sildenafil Dose Optimization · For: Pulmonary Arterial Hypertension (PAH)
Sites: São Paulo, Brazil
- Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female SubjectsPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT02206204 · 159 participants · Start Jun 2012 · Primary completion Nov 2012
Drug: selexipag; placebo for selexipag and 2 more · For: Cardiodynamics; Safety; Tolerability and 1 more
Sites: Evansville, Indiana
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial HypertensionPivotal-lookingActive, not recruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT04175600 · 138 participants · Start Jan 16, 2020 · Primary completion Oct 11, 2024
Drug: Selexipag; Placebo and 3 more · For: Hypertension, Pulmonary
Sites: Phoenix, Arizona; Los Angeles, California; San Francisco, California · 116 sites in all
- A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional TreatmentPivotal-lookingTerminated
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT03689244 · 128 participants · Start Jan 23, 2019 · Primary completion Jun 7, 2022
Drug: Selexipag; Placebo · For: Chronic Thromboembolic Pulmonary Hypertension
Sites: La Jolla, California; Los Angeles, California; Aurora, Colorado · 162 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache6,834
- diarrhoea5,244
- dyspnoea4,841
- nausea4,153
- fatigue2,651
- death2,559
- pain in jaw2,455
- dizziness2,338
- pain2,250
- pain in extremity2,149
- myalgia2,008
- vomiting1,970
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 26 |
| 2016 | 1,557 |
| 2017 | 2,388 |
| 2018 | 3,027 |
| 2019 | 3,219 |
| 2020 | 3,248 |
| 2021 | 2,807 |
| 2022 | 2,261 |
| 2023 | 2,301 |
| 2024 | 2,240 |
| 2025 | 1,807 |
| 2026 | 1,210 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Uptravi* (Selexipag)
2024 spending
$909M
Beneficiaries
4,320
39,389 claims
Per beneficiary
$210,364
$354.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $540,954,176 |
| 2021 | $614,909,881 |
| 2022 | $582,841,269 |
| 2023 | $758,070,464 |
| 2024 | $908,772,074 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O, Channick R, Chin KM, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Multicenter Study
- Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Chin KM, Sitbon O, Doelberg M, et al. · J Am Coll Cardiol 2021 · Clinical Trial, Phase III, Comparative Study
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
Erdogan M, Esatoglu SN, Kilickiran Avci B, et al. · Intern Emerg Med 2024 · Systematic Review, Meta-Analysis
- Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.
Baker WL, Darsaklis K, Singhvi A, et al. · Ann Pharmacother 2017 · Systematic Review
- Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial).
Kim NH, Channick R, Delcroix M, et al. · Eur Respir J 2024 · Randomized Controlled Trial, Multicenter Study
- Prostacyclin for pulmonary arterial hypertension.
Barnes H, Yeoh HL, Fothergill T, et al. · Cochrane Database Syst Rev 2019 · Systematic Review
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.